Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11840579 Bispecific antibodies that bind to CD38 and CD3

Patent 11840579 was granted and assigned to Xencor on December, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity

All edits

Edits on 13 Dec, 2023
"Created via: Patent importer"
Golden AI profile picture
Golden AI
created this topic on 13 Dec, 2023
Edits made to:
Infobox (+46 properties)
Article (+102 characters)
‌

 US Patent 11840579 Bispecific antibodies that bind to CD38 and CD3

Article

Patent abstract

The invention provides novel heterodimeric proteins including heterodimeric antibodies.

Infobox
Is a
Patent
Patent
0
Patent Applicant
Xencor
Xencor
0
Current Assignee
Xencor
Xencor
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
118405790
Patent Inventor Names
Gregory Moore0
John Desjarlais0
Matthew Bernett0
Seung Chu0
Date of Patent
December 12, 2023
0
Patent Application Number
170862130
Date Filed
October 30, 2020
0
Patent Citations
‌
US Patent 7087600 Peptidyl prodrugs and linkers and stabilizers useful therefor
0
‌
US Patent 7112324 CD 19×CD3 specific polypeptides and uses thereof
0
‌
US Patent 7129261 Cytotoxic agents
0
‌
US Patent 7276497 Cytotoxic agents comprising new maytansinoids
0
‌
US Patent 7303749 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
0
‌
US Patent 7368565 Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
0
‌
US Patent 7498302 Disulfide prodrugs and linkers and stabilizers useful therefor
0
‌
US Patent 7507420 Peptidyl prodrugs and linkers and stabilizers useful therefor
0
‌
US Patent 7517903 Cytotoxic compounds and conjugates
0
‌
US Patent 7601354 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
0
‌
US Patent 7642228 Method for making heteromultimeric polypeptides
0
‌
US Patent 7691962 Chemical linkers and conjugates thereof
0
‌
US Patent 7695936 Knobs and holes heteromeric polypeptides
0
‌
US Patent 7696338 Immunotoxin fusion proteins and means for expression thereof
0
‌
US Patent 7728114 Anti-CD3 antibodies and methods of use thereof
0
‌
US Patent 8063187 Methods and compositions for inhibiting CD32B expressing cells
0
‌
US Patent 8114967 Constructs and libraries comprising antibody surrogate light chain sequences
0
‌
US Patent 8216805 Knobs and holes heteromeric polypeptides
0
‌
US Patent 8236308 Composition comprising cross-species-specific antibodies and uses thereof
0
‌
US Patent 8309690 Integrated approach for generating multidomain protein therapeutics
0
‌
US Patent 8367805 Fc variants with altered binding to FcRn
0
‌
US Patent 8409568 Mutant antibody Fc domains and fusion proteins thereof
0
‌
US Patent 8592562 Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
0
‌
US Patent 8637641 Antibodies with modified isoelectric points
0
‌
US Patent 8946387 FcγRIIB specific antibodies and methods of use thereof
0
‌
US Patent 9181334 Pharmaceutical composition for treatment and/or prophylaxis of cancer
0
‌
US Patent 9822181 Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof
0
‌
US Patent 9856327 Heterodimeric antibodies to CD3 X CD123
0
‌
US Patent 10227410 Heterodimeric antibodies that bind CD3 and PSMA
0
‌
US Patent 10428155 Trispecific antibodies
0
‌
US Patent 10526417 Heterodimeric antibodies that bind CD3 and CD38
0
‌
US Patent 6884869 Pentapeptide compounds and uses related thereto
0
‌
US Patent 6989452 Disulfide prodrugs and linkers and stabilizers useful therefor
0
Patent Primary Examiner
‌
Mark Halvorson
0

Find more entities like US Patent 11840579 Bispecific antibodies that bind to CD38 and CD3

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.